Price
$1.37
Decreased by -8.67%
Dollar volume (20D)
1.95 M
ADR%
11.68
Earnings report date
Jul 30, 2025
Shares float
46.60 M
Shares short
6.41 M [13.75%]
Shares outstanding
71.01 M
Market cap
112.19 M
Beta
3.11
Price/earnings
N/A
20D range
1.09 1.79
50D range
1.08 2.45
200D range
1.08 7.36

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.

Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma.

The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer.

It has strategic collaborations with F.

Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC.

The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 6, 25 -0.37
Increased by +9.76%
-0.35
Decreased by -5.71%
Feb 20, 25 -0.49
Increased by +30.00%
-0.45
Decreased by -8.79%
Oct 31, 24 -0.35
Increased by +32.69%
-0.38
Increased by +7.89%
Aug 1, 24 -0.26
Increased by +64.38%
-0.37
Increased by +29.73%
May 8, 24 -0.41
Increased by +42.25%
-0.35
Decreased by -17.14%
Feb 22, 24 -0.70
Increased by +9.09%
-0.68
Decreased by -2.94%
Nov 1, 23 -0.52
Increased by +20.00%
-0.66
Increased by +21.21%
Aug 8, 23 -0.73
Decreased by -30.36%
-0.69
Decreased by -5.80%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Dec 31, 24 5.18 M
Increased by +58.75%
-34.57 M
Increased by +0.52%
Decreased by -667.82%
Increased by +37.34%
Sep 30, 24 15.36 M
Increased by +38.75%
-24.67 M
Increased by +8.77%
Decreased by -160.57%
Increased by +34.25%
Jun 30, 24 12.01 M
Increased by +350.68%
-17.72 M
Increased by +50.68%
Decreased by -147.56%
Increased by +89.06%
Mar 31, 24 3.04 M
Decreased by -19.15%
-28.36 M
Increased by +16.43%
Decreased by -933.23%
Decreased by -3.37%
Dec 31, 23 3.26 M
Increased by +14.26%
-34.75 M
Increased by +3.67%
Decreased by -1.07 K%
Increased by +15.69%
Sep 30, 23 11.07 M
Increased by +63.93%
-27.04 M
Increased by +13.97%
Decreased by -244.19%
Increased by +47.52%
Jun 30, 23 2.66 M
Decreased by -80.74%
-35.92 M
Decreased by -30.91%
Decreased by -1.35 K%
Decreased by -579.81%
Mar 31, 23 3.76 M
Decreased by -50.89%
-33.94 M
Decreased by -6.49%
Decreased by -902.85%
Decreased by -116.82%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY